Listed by the USPTO as DAHLIN, HEATHER RAQUEL
Tech Center 1600 • Art Units: 1628 1629
This examiner grants 42% of resolved cases
DAHLIN, HEATHER RAQUEL is a USPTO patent examiner in Tech Center 1600 and Art Unit 1628. The record covers 168 resolved cases, with a 42.3% allowance rate and a median of 1233 days to allowance. Interviews are associated with a 46.6% lift, a substantial relationship within the reported outcomes.
The leading companies are Hoffmann-La Roche Inc., King's College London, and Peloton Therapeutics Inc. A Fully Owned Subsidiary Of Merck Sharp & Dohme LLC. The leading firms are BIRCH STEWART KOLASCH & BIRCH, LLP, NOVICK, KIM & LEE, PLLC, dba NKL Law, and OLIFF PLC. Counsel may want to treat interviews as an important part of prosecution planning while budgeting for a 1233-day median.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18823182 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 18255076 | NEW INDAZOLE DERIVATIVES | Final Rejection | Hoffmann-La Roche Inc. |
| 18730353 | Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397) | Non-Final OA | AMGEN INC. |
| 17622121 | COMPOUNDS HAVING ANTIMALARIAL ACTIVITY | Non-Final OA | NANYANG TECHNOLOGICAL UNIVERSITY |
| 18023211 | KAEMPFEROL AGLYCONE-CONTAINING EXTRACT | Final Rejection | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18265335 | COMPOSITIONS AND METHODS FOR INHIBITING M PRO PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-COV-2 INFECTION | Final Rejection | Arizona Board of Regents on Behalf of the University of Arizona |
| 17993922 | METHOD FOR SCREENING MARKERS FOR PREDICTING PROGNOSIS OF RENAL CELL CARCINOMA USING TRANSCRIPTOMIC ANALYSIS | Non-Final OA | Gwangju Institute of Science and Technology |
| 18269526 | COMBINATION THERAPY WITH A VINCA ALKALOID N-OXIDE AND AN IMMUNE CHECKPOINT INHIBITOR | Non-Final OA | CASCADE PRODRUG INC. |
| 18514697 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSOMNIA | Final Rejection | Individual inventor |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy42.3% of resolved applications examined by Heather Raquel Dahlin were allowed (168 resolved cases), compared with 25.9% across Art Unit 1628 over the last five years.
This examiner's interview lift is +46.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Heather Raquel Dahlin took 1,233 days on average from filing to allowance.
Heather Raquel Dahlin examines applications in Art Unit 1628 in Tech Center 1600 (Biotechnology & Pharmaceuticals).